Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocept Inc BIOCQ

Healthcare Biotechnology
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Recent & Breaking News (GREY:BIOCQ)

Biocept Reports Second Quarter 2022 Financial Results

Business Wire November 10, 2022

Biocept to Present at the LD Micro Main Event XV

Business Wire October 19, 2022

Biocept Expands Commercial Offering of CNSide(TM) Assay to Most Cancers that Metastasize to the Central Nervous System

Business Wire October 17, 2022

Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide(TM) Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

Business Wire October 14, 2022

Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide(TM) Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

Business Wire October 6, 2022

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 31, 2022

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Business Wire August 22, 2022

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

Business Wire August 16, 2022

Biocept Appoints RSM as Independent Auditor

Business Wire June 27, 2022

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

GlobeNewswire June 22, 2022

Biocept to Hold Business Strategy Conference Call Today

Business Wire June 7, 2022

Biocept Reports First Quarter 2022 Financial Results

Business Wire May 23, 2022

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

Business Wire May 16, 2022

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 8, 2022

Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

Business Wire April 6, 2022

Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

Business Wire March 31, 2022

Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

Business Wire March 18, 2022

Biocept Appoints Philippe Marchand as Chief Operating Officer

Business Wire March 8, 2022

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 4, 2022

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide(TM) Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

Business Wire February 22, 2022